

# Index

## A

- Acidosis
  - exercise, 310
  - gastrointestinal tract, 301–305, 316
  - inflammation, 285, 301, 306–308, 310, 312, 316
  - ischaemia, 284, 301, 306, 309, 316
  - osteoclastic bone resorption, 310, 311
  - urogenital tract, 305–306
- Acid-sensing ion channels (ASICs), 237, 242
  - ASIC1, 287–289, 312–314
  - ASIC2, 287–289, 313
  - ASIC3, 287–289, 313
  - ASIC blockers, 312
  - nonsteroidal antiinflammatory drugs, 308, 312, 313
- Adenosine, 145, 146, 153–156, 159, 160
  - aminophylline, 208, 209
  - A<sub>1</sub> receptor, 208
  - A<sub>2</sub> receptor, 208
- Adenosine triphosphate (ATP), 143, 145, 146, 152, 155, 234, 237, 238, 243
- Adenoviral vectors, 600
- A-fiber, 146, 160, 162
- Afferent nerves
  - A $\delta$ , 101, 112, 113, 127
  - bladder, 99, 100, 105, 110, 123
  - C-fiber, 121, 127
  - chemosensitive, 106
  - mechanosensitive, 103, 104, 111, 121, 127
  - mucosal, 106
  - muscular, 105
  - myelinated, 94, 97, 99, 104, 127
  - pelvic floor, 103–106, 110, 112–114, 123
  - unmyelinated, 97–99, 103, 104, 114, 127
  - urethral, 103, 106, 114
  - urothelial, 101, 105, 115
- Afterhyperpolarization (AHP), 569–572, 581
- Agatoxin, 566
- Agonists, 267–269, 273–275
- Airway smooth muscle, 141, 143, 144, 146, 148–151, 158, 160, 165
- Allergic, 159, 162
- Allergic rhinitis, 156, 165
- Allodynia, 590, 591, 595–597, 599, 605
- 4-Aminopyridine (4-AP), 107, 109, 117, 119
- Analgesia, 497, 503–509
- Anandamide, 146, 147
- Animal model, 33, 57
- Antagonists, 268, 273–275
- Antiarrhythmic drugs, 533–537
  - binding site, 534
  - classification, 534–535
- Anticonvulsant drugs, 537–539
  - binding site, 537
  - blockade of persistent sodium current, 539
  - mechanism of block, 538
  - use in neuropathic pain, 538–539
- Antinociception, 503, 505–507
- Apamin, 569, 572

Apnea, 148, 153  
 Assessment, 24  
 Asthma, 140, 152, 158–160, 162, 165, 167  
 Axon reflex, 152–153

## B

Batrachotoxin, 537, 539, 543–545, 547, 548  
 1, 2-Bis(O-aminophenoxy) ethane-N,N,N',  
 N'-tetraacetic acid (BAPTA), 571  
 BK channels, 569, 572  
 Bladder, 32–34, 36, 37, 41–49, 51–54, 58,  
 60, 348, 355, 357–359, 368–369, 379  
 Bladder outlet obstruction (BOO), 119–121  
 Bladder reflexes, 113, 117  
 Botulinum neurotoxin, 115, 119  
 Bradycardia, 153  
 Bradykinin, 146, 148, 150, 153–157, 159,  
 160, 166, 238, 571, 576, 577  
 C-fiber, 211, 212  
 visceral afferent, 211, 212  
 Bradykinin (BK) and Histamine  
 cyclooxygenase, 211, 213  
 facilitation, 211  
 hyperalgesia, 211  
 Bradykinin (BK) receptor  
 BK<sub>1</sub> receptor, 190, 191  
 BK<sub>2</sub> receptor, 190–191  
 HOE<sub>140</sub>, 191  
 NPC-17731, 191  
 Brain-derived neurotrophic factor (BDNF),  
 601–605  
 Brain–gut axis, 35, 59  
 Brain stem, 349, 351, 354, 356, 371, 372  
 Brevetoxin, 539, 546  
 Bronchial hyperresponsiveness (BHR),  
 158–160, 162, 163, 165–167  
 Bronchospasm, 141, 143, 145, 150–152,  
 154, 156, 157, 160

C

Ca<sup>2+</sup> channels, L-type, 298, 316  
 Calcitonin gene-regulated peptide (CGRP),  
 602, 603, 605  
 Calcitonin gene-related peptide (CGRP),  
 77–84, 145, 152, 162, 165, 230, 231, 453,  
 456–463, 466, 467, 478, 479

Calcium channels, 565–568, 591, 593, 594  
 Calcium-induced calcium release (CICR),  
 574, 577, 578  
 Calmodulin, 575–578  
 Cannabinoid(s), 248, 605–606  
 Capsaicin, 142–148, 152–157, 162, 165,  
 166, 590, 602, 604  
 Carbamazepine, 537–539  
 Cardiac afferent  
 angina, 186, 187, 191, 192, 194, 196, 198,  
 199, 202, 210, 216  
 excitability, 185–216  
 myocardial ischemia, 187–200, 202–204,  
 206–213, 215  
 Carotid body, 308–309, 340, 344, 345,  
 375  
 Ca<sub>v</sub>, 565  
 CCL2, 597  
 Central nervous system (CNS), 156–157  
 C-fibers, 141–148, 150, 153–156, 162, 165,  
 166  
*c-fos*, 97, 98, 123  
 CGRP receptor, 80, 83–85  
 Channels, 263–275  
 Charybdotoxin, 569  
 Chemokine, 417–441  
 Cholecystokinin, 238, 248, 605  
 Chronic obstructive pulmonary disease  
 (COPD), 140, 151, 152, 154, 167  
 Ciguatoxin, 539, 546  
 Citric acid, 154, 155, 162  
 c-Jun N-terminal kinase (JNK), 598, 599  
 Cl<sup>-</sup> channels, acid-sensitive, 291, 298  
 Clodronate, 596  
 CO<sub>2</sub>, 140–142, 144, 147, 154  
 Cold air, 159  
 Colon, 33–37, 39, 43, 49–56, 58, 59  
 Compliance, 141, 143, 151, 154  
 Conduction velocity, 141, 144, 146, 148  
 Confocal, 576  
 Conotoxin, 336, 539, 567, 592  
 μ-Conotoxins, 540, 542, 547  
 Cooling, 147  
 Cotransmitter, 348, 355, 356, 362, 366  
 Cough, 142, 144, 145, 147, 154–157, 162,  
 167  
 Cough receptor, 147–149, 154

Current, proton-gated, 285–287, 289, 291  
 Cyclic AMP response element binding protein (CREB), 461, 462, 466, 467, 476  
 Cyclic-nucleotide-gated channels, hyperpolarization-activated, 298, 300, 316  
 Cyclooxygenase-2, 125  
 Cyclophosphamide, 95, 122–125  
 Cystitis, 95, 121–125  
 Cytokine, 417–441, 595–598, 601

## D

Depolarization, 565, 569, 573–575, 581  
 Development, 347–349, 364, 366, 370–375, 379  
 Diabetes, 126  
 Diabetic induced neuropathy, 581  
 Distilled water, 159, 160  
 DNA, 600  
 Dorsal root ganglia (DRG), 93–95, 97–100, 107–110, 115–118, 122, 124–126, 231, 238, 418, 419, 421, 422, 425–430, 432–441, 591–594, 597–600, 602–604  
 Dorsal root ganglion (DRG), 285, 286, 289, 291, 292, 295–297, 299, 303–311, 313, 315, 564, 565, 573, 576–581  
 Dysphagia, 246  
 Dyspnea, 153, 154

## E

Ear, 335, 348–349, 367–368, 375  
 Edema, 141, 143, 162  
 Electrophysiological, 148, 152, 156, 157, 161  
 Evolution, 375–378  
 Excitability, 563–582  
 Exercise, 151, 159  
 Extracellular-signal-regulated kinase (ERK), 598, 599, 604  
 Eye, 340, 349, 367

## F

Flecainide, 534–537  
 Furosemide, 154

## G

Gabapentin, 581, 590, 594  
 GABA receptors, GABA<sub>A</sub>, 298  
 Galanin, 240, 241  
 $\gamma$ -amino butyric acid (GABA), 237, 240  
 Gap junctions, 18, 78, 103, 298  
 Gap junction channels, 298, 316  
 Gastrointestinal tract  
   abdominal pain, 303–305  
   acid hyperresponsiveness, 303  
   acid-induced hyperaemia, 302  
   acid-induced pain, 303–305  
   acidosis, 301–305, 316  
   colitis, 304, 305  
   gastric acid, 284, 301–303  
   gastric acid secretion, 284  
   gastritis, 301, 303  
   mucosal injury, 303  
 Gastro-oesophageal reflux disease, 240, 241, 243–249  
 Gene therapy, 599–601  
 Ghrelin, 241  
 Glucocorticosteroid, 160  
 Glutamate receptors  
   ionotropic, 237, 239  
   metabotropic, 237, 241, 248  
 Glycoprotein IIb-IIIa receptor inhibitor, 193  
   tirofiban, 193–195, 197  
 G-protein coupled receptors  
   G2A, 296  
   GPR4, 296  
   OGR1, 296  
   proton-sensing, 287, 296  
   TDAG8, 296  
 Guarded receptor hypothesis, 531  
 Gut, 347–348, 357, 358, 360, 369–370

## H

Heartburn, 244, 245  
 Hering-Breuer reflex, 141  
 High-threshold mechanoreceptors, 234  
 Histamine, 143, 145, 147, 150, 152, 153, 159, 571, 572  
   mast cell, 198, 199  
   release, 198, 199, 211, 212, 215  
   sensory nerve, 199, 211

- Histamine receptor  
 agonist, 200  
 antagonist, 200  
 H<sub>1</sub> receptor, 198–201, 215  
 H<sub>2</sub> receptor, 200  
 pyrilamine, 200
- 5-HT receptor  
 agonist  
 antagonist  
 5HT<sub>3</sub> receptor  
 tropisetron
- 5-Hydroxytryptamine (5-HT), 232, 237–239  
 A $\delta$  afferent, 197  
 nociception, 194, 197  
 release, 195, 196  
 stimulation, 195, 197, 198
- Hyperalgesia, 122, 124, 125, 453–455,  
 460–463, 467, 469–476, 478, 590,  
 595–597, 601–604
- Hyperpnea, 141, 151
- Hypertonic saline, 153, 159, 160
- Hypoxia, 345, 347, 354, 379
- I**
- Iberiotoxin, 569, 572
- Idiopathic detrusor overactivity (IDO), 119
- IK channel, 569
- IL-1 $\beta$ , 422–426, 428, 429, 440, 505, 506,  
 597
- IL-6, 597
- Immune cell, 496, 503–507, 509
- Immunohistochemical, 145, 146
- Inflammation, 232, 234, 238, 239, 242, 243,  
 360, 362, 365, 369, 418, 420–422, 427,  
 429, 430, 432, 433, 453, 456, 459, 461–  
 463, 466–468, 471–473, 496, 497, 500–  
 501, 503, 505–509
- Inflammatory mediators, 102, 105, 127
- Interactions, 192, 209–215
- Interorgan cross-sensitization, 126–127
- Interstitial cystitis (IC), 93, 121–125
- Intraganglionic laminar endings (IGLEs),  
 229–231
- Intramuscular arrays (IMAs), 229, 230
- Ion channels  
 acid sensing (ASIC), 111  
 A-type K<sup>+</sup> (I<sub>A</sub>), 107, 119  
 calcium (Ca<sup>2+</sup>), 109–110  
 L-type Ca<sup>2+</sup>, 109  
 Na<sub>v</sub>1.8, 109  
 Na<sub>v</sub>1.9, 108  
 N-type Ca<sup>2+</sup>, 109  
 potassium (K<sup>+</sup>), 108–109, 118–119  
 sodium (Na<sup>+</sup>), 108, 118–119  
 TTX-resistant (Na<sup>+</sup>), 108, 109, 111, 119,  
 126  
 TTX-sensitive (Na<sup>+</sup>), 108, 118–120  
 T-type Ca<sup>2+</sup>, 110
- Irritable bladder, 162
- Irritant, 143, 146
- J**
- Jugular ganglia, 229, 238
- Jugular ganglion, 145, 146, 155
- K**
- K<sup>+</sup> channels  
 Kir6.1, 298  
 K<sub>2P</sub>, 287, 293–296, 299, 308, 312,  
 315–316  
 K<sub>v</sub>1.3, 298  
 K<sub>v</sub>1.4, 298  
 K<sub>v</sub>11.1, 298
- KCNQ, 593
- Knockout, 165–167
- K<sub>v</sub>1, 593
- K<sub>v</sub>2, 593
- K<sub>v</sub>7, 593
- L**
- Leukocyte, 497, 498, 503, 504, 507, 509
- Lidocaine, 529–534, 539
- Local anaesthetics, 529–533  
 binding site, 530–533  
 mechanism of channel block, 531  
 subtype selectivity, 532
- Lower urinary tract, 92–98
- Low-threshold mechanoreceptors,  
 232–234
- L-type calcium channel, 593, 594
- Lumbar splanchnic nerve (LSN), 38–43, 49,  
 54, 55

Lung, 344, 346–347, 351, 358, 371, 375  
Lung inflation, 141–144, 150

## M

Macrophage, 595–597  
Motor cortex stimulation (MCS), 606, 607  
Mechanosensory transduction, 357–361, 378, 379  
Menthol, 102, 105  
Methacholine, 143, 159, 160  
Methotrexate, 596  
 $\alpha,\beta$ -Methylene-ATP, 106, 110, 111  
Mexiletine, 534, 535  
Microglia, 596–599, 601  
Micturition, 104, 112–116, 119, 120  
Migraine, 162  
Mitochondria, 564, 574–576, 579–581  
Modulated receptor hypothesis, 530, 531  
Mucosal afferents, 231, 241  
Mucus secretion, 144, 149–152  
Myocardial reflex, 187  
Myocardium, 299, 310  
Myofibroblasts, 101, 103

## N

$\text{Na}^+$  channels, tetrodotoxin-sensitive, 298  
 $\text{Na}^+ - \text{K}^+$ -ATPase, 141, 149  
 $\text{Na}_v1.3$ , 591, 592  
 $\text{Na}_v1.7$ , 591, 592  
 $\text{Na}_v1.8$ , 591, 592, 602  
 $\text{Na}_v$  channels, 591, 592, 602  
Nerve growth factor (NGF), 601–604  
Nerve growth factor (NGF) antibodies, 118  
Nerve injury, 581–582  
Nerves  
  bladder, 126  
  hypogastric, 92, 93, 98, 99, 106  
  pelvic, 92–94, 98, 99, 103–106, 112–114  
  pudendal, 92–94, 98, 99, 113, 114  
  urethral, 94, 103, 106, 114  
  urethral sphincter, 112  
  urinary bladder, 121, 126  
  urinary tract, 93, 98, 103  
Neurogenic detrusor overactivity (NDO), 115, 119  
Neurogenic vasodilatation, 82

Neurokinin, 145, 150, 152, 157, 162, 165, 453, 459, 463–478  
Neuropathic pain (NP), 589–607  
Neuropathy, 15–17, 19, 23  
Neuropeptide(s), 393–409, 602, 605  
  CGRP, 402–405  
    CGRP receptors, 402  
  galanin, 405–408  
    galanin receptors, 406  
  substance P, 396–401  
  tachykinins, 396–401  
    tachykinin receptor antagonists, 401  
    tachykinin receptors, 397  
Neuroplasticity, 125  
Neurostimulation, 606–607  
Neurotransmitters  
  acetylcholine (ACh), 103  
  aspartic acid, 99  
  ATP, 102  
  bradykinin, 102, 121  
  calcitonin-gene-related peptide (CGRP), 94, 99  
  corticotropin releasing factor (CRF), 99  
  glutamic acid, 99  
  histamine, 121  
  neuropeptides, 99, 100, 102, 104  
  nitric oxide, 99, 101, 102, 109, 114  
  norepinephrine, 102  
  pituitary adenylate cyclase activating polypeptide (PACAP), 94, 99, 115, 116, 122  
  prostaglandin E, 97  
  prostaglandins, 103  
  purinergic, 100, 110  
  purines, 102  
  serotonin (5HT), 97, 121  
  vasoactive intestinal polypeptide (VIP), 99, 104  
Neurotrophic factors  
  brain derived neurotrophic factor (BDNF), 100, 122  
  CTNF, 122  
  glial cell line derived neurotrophic factor (GDNF), 100, 122  
  nerve growth factor (NGF), 100, 103, 117–118, 121, 122, 126  
Neutrophil, 595, 602  
Nitric oxide, 248

- Nitric oxide synthase (NOS), 99  
 N-methyl-D-aspartate (NMDA), 590, 604  
 Nociception, 349, 360, 362, 364, 370  
 Nociceptors, 266, 271  
 Nodose ganglia, 229, 238–241  
 Nodose ganglion, 162, 289, 292, 297, 303, 305, 306, 311  
 Nodose ganglion neurone (NGN), 564, 573, 578, 581  
 Non-cardiac chest pain, 244–246  
 Non-erosive reflux disease, 245  
 N-type calcium channel, 593, 594  
 Nuclear factor of activated T cells (NFAT), 476–478  
 Nucleus of solitary tract (nTS), 156, 157, 166
- O**  
 Olvanil, 146, 147  
 Opioid(s), 153, 157, 241, 248  
   peptide, 496–498, 502–507, 509  
   receptor, 496–503, 505–509  
   tolerance, 508  
 Osmolarity, 147  
 Ouabain, 141
- P**  
 Paclitaxel, 580, 581  
 Pain, 263–275, 418–425, 427, 429–441, 496, 497, 501, 502, 504–509  
   acid-induced, 303–305  
   inflammation-induced, 285, 312  
   tumour-induced, 285  
 Painful bladder syndrome (PBS), 121–125  
 Parasympathetic, 149–152  
 Parasympathetic nucleus, 96, 97, 99  
 Patch clamp, 95, 107, 110, 116, 118, 120, 123  
 Pathophysiology, 5, 8, 25  
 Pelvic nerve (PN), 37–45, 47, 49–57, 59  
 Phasic firing, 96, 107, 109, 124  
 Phenytoin, 537–539  
 Phospholipase C (PLC), 197, 201, 204  
 Plasma membrane calcium ATPase (PMCA), 574–577, 581  
 Platelets  
   activation, 192–194, 202, 215  
   collagen, 192–196  
   granules, 191, 192, 215  
   platelet-rich plasma, 194, 196  
 P38 MAPK, 598, 599  
 Polymorphonuclear leukocyte, antibody, 207  
 Primary afferents, 33, 37–39, 49, 53, 59  
 Primary sensory neurons, 77, 79, 84, 85  
 Propentofylline, 596  
 Prostaglandin(s), 147, 153, 154, 237, 239, 245, 571, 572  
 Prostaglandins and BK  
   desensitization, 212  
   sensitization, 210  
 Protease, 146, 147  
 Protein kinase, 598–599  
 Protein kinase A (PKA), 526–529, 532, 576, 577  
 Protein kinase C (PKC), 109, 125, 526–529, 576–579  
   inhibitor, 201  
 Protons  
   acid-sensing ion channels (ASIC), 189  
   epicardial pH, 188  
   lactic acid, 188, 189  
   vanilloid receptor, 189  
 Pulmonary system, acid-induced cough, 306, 307  
 Purinoceptors  
   P2X<sub>1</sub>, 296, 297, 305  
   P2X<sub>2</sub>, 287, 296, 297, 306, 308  
   P2X<sub>3</sub>, 296–298, 305, 306  
   P2X<sub>4</sub>, 296, 297  
   P2X<sub>5</sub>, 296, 297  
   P2X<sub>7</sub>, 296, 297  
 P2X receptors, 238  
 Pyrethroids, 547
- Q**  
 QX314, 530–533
- R**  
 Rapidly adapting receptors (RARs), 141–144  
 Reactive oxygen species  
   chelating, 206  
   deferoxamine, 206, 207

dimethylthiourea, 206  
 $H_2O_2$ , 204–207  
 hydroxyl radicals, 204  
 scavenger, 206  
 Receptor(s), 453–479  
   capsaicin receptor, 100, 102  
   CREB, 122  
   endothelin, 100  
   GDNF, 100, 122  
   GRF $_{\alpha}$ , 100  
   IB4, 100, 111, 125  
   muscarinic, 100, 127  
   neurokinin, 102, 109, 125  
   nicotinic, 100, 101  
   NK-2, 102, 109  
   purinergic, 100, 110, 123  
   P2X $_2$ , 100, 110, 123  
   P2X $_3$ , 100, 110, 115, 119, 123  
   P2Y, 100, 103  
   stretch, 102, 105, 106  
   TrkA, 100, 102, 122  
   TrkB, 100, 122  
   TRPA1, 100  
   TRPM8, 100, 102, 105, 117  
   TRPV1, 99, 100, 102, 110, 119, 125  
 Resiniferatoxin, 99, 115, 118, 119, 122, 123, 125  
 RNA, 600  
 Ryanodine receptor (RyR), 574, 577, 578

## S

Sarcoplasmic reticulum/ER calcium  
   ATPase (SERCA), 574, 578, 579  
 Saxitoxin, 540–542  
 Scorpion toxins, 545–546  
 Sensory ganglia, 347, 372, 374  
 Sensory system, 262, 263  
 Serotonin, 143, 145, 153, 155–157  
 Sites 3–9 toxins, 545–547  
 Site 1 toxins, 540–543  
    $\mu$ -conotoxins, 542–543  
   tetrodotoxin and saxitoxin, 540–542  
 Site 2 toxins, 543–545  
   binding site, 543  
   mechanism of action, 544  
   subtype selectivity, 544  
 SK channel, 569, 570, 572

Skeletal muscle, 289, 309–310  
 Skeleton, acid-induced pain, 310, 311  
 Skin, acid-induced pain, 307, 308  
 Slowly adapting receptors (SARs),  
   141–144, 148, 150, 151, 154,  
   156, 157  
 Sodium–calcium exchanger (NCX), 574,  
   575, 577, 579  
 Somatostatin, 242  
 Sour taste, 285, 286, 293, 299–301  
 Spinal afferents, 230–234, 238–241, 243  
 Spinal cord, 93, 94, 96–100, 104, 112–114,  
   120, 123, 125, 335, 351, 352, 360–362,  
   364–366, 369, 372, 453, 456–461,  
   463–478  
 Spinal cord injury (SCI), 104, 114–119  
 Spinal interneurons, 96, 126  
 Substance P, 145, 146, 152, 157, 162, 165,  
   453, 456, 459, 460, 462–464, 466–468,  
   470–479  
 Sulfur dioxide, 141, 155, 159, 160  
 Sympathetic, 151–152

## T

TALK-1, 295, 296  
 TALK-2, 295, 296  
 TASK-1, 294–296, 308, 316  
 TASK-2, 294–296  
 TASK-3, 294–296, 308, 309, 316  
 TASK-5, 294, 308  
 Taste buds, 350  
 Tension/mucosal receptors, 233  
 Tension receptors, 232–233, 237, 238,  
   240–242, 247  
 Tetrodotoxin (TTX), 96, 107–109, 111,  
   117–121, 124, 126, 540–542, 592  
   binding site, 540, 541  
   subtype selectivity, 541  
   trapped ion mechanism, 540  
   use-dependent activity, 540  
 Thrombin, 146  
 Thromboxane A $_2$   
   cyclooxygenase, 202, 203, 214  
   generation, 215  
   U46619, 202–204  
 Thromboxane A $_2$  and BK  
   mediator, 213, 215

phospholipase A<sub>2</sub>, 214  
 reciprocal interaction, 213, 216  
 summation, 215  
 Tongue, 350, 361, 362, 374  
 Tonic firing, 96, 107, 109  
 Tooth pulp, 360–362  
 Toxin binding sites, 539–541  
 TP receptor  
   antagonist, 203  
   BM13177, 203, 204, 215  
   location, 202, 203  
   PKC pathway, 204  
   sensory neuron, 204  
 Transcutaneous electrical nerve stimulation (TENS), 606  
 Transient lower oesophageal sphincter relaxation (TLOSR), 246–249  
 Transient receptor potential channel, 242  
 Treatment, 19–24, 26  
 TRESK, 295, 296  
 Trigeminal neurone, TG, 565, 573, 576, 579, 580  
 trkA, 602, 603  
 trkB, 604  
 TRPA1, 263, 266–267, 270–275  
 TRPC4, 286, 292, 316  
 TRPC5, 284, 286, 292, 316  
 TRPM8, 263, 266–268, 271–275  
 TRPP2 (PKD2L1), sour taste, 293, 300  
 TRPV1, 144, 146–148, 152–155, 157, 162, 165–167, 263, 265–275  
   capsaicin, 290, 291, 303–307, 315  
   capsazepine, 302, 304, 306, 307, 309–311, 314, 315  
   TRPV1 blockers, 291, 304, 307, 311, 314, 315  
 TRPV2, 265, 269, 273, 275  
 TRPV3, 263, 265, 269, 270, 272, 273, 275  
 TRPV4, 263, 265–266, 270, 272, 275, 286, 292, 304, 316  
 Tumour necrosis factor (TNF), 597  
 TWIK-1, 295, 296

## U

Urogenital tract, acid-induced hyperreflexia, 305  
 Uroplakins, 101  
 Urothelium, 94, 99, 101–103, 105, 106, 109, 115, 120, 123, 125

## V

Vagal afferents, 229–233, 239–243, 247–249  
 Vanilloid receptors, 237, 239, 242  
 Vascular, 141, 143, 144, 149, 152, 160  
 Veratradine, 141  
 Veratridine, 535, 543, 544, 547, 548  
 Viral vectors, 598, 600, 601  
 Visceral pain, 32–60  
 Voiding, 104, 111–114, 116–118, 123, 127  
 Voltage-dependent calcium channels (VDCC), 564, 565, 568, 571–575, 581, 593, 594  
 Voltage-gated sodium channels (VGSC), 519–549  
   classification, 523–526  
   distribution, 523–526  
   function, 522–523  
   phosphorylation, 526–528  
   structure, 521–522  
    $\beta$ -subunits, 521, 522  
   use-dependent blockade, 530

## X

Xanthine oxidase  
   inhibition, 207  
   oxypurinol, 207

## Z

Ziconotide, 594